Telix Historical Income Statement

TLX Stock

24.62 0.12 0.49%

Historical analysis of Telix Pharmaceuticals income statement accounts such as Total Operating Expenses of 327.1 M, Income Before Tax of 3.2 M, Net Income of 5.5 M or Depreciation And Amortization of 7.1 M can show how well Telix Pharmaceuticals performed in making a profits. Evaluating Telix Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Telix Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Telix Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telix Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Telix Income Statement Analysis

Telix Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Telix Pharmaceuticals shareholders. The income statement also shows Telix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Telix Pharmaceuticals Income Statement Chart

At this time, Telix Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Total Revenue is likely to gain to about 521.5 M in 2024, despite the fact that Net Loss is likely to grow to (89 M).

Interest Expense Operating Income Income Before Tax Income Tax Expense

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Operating Income

Operating Income is the amount of profit realized from Telix Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Telix Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Telix Pharmaceuticals income statement and is an important metric when analyzing Telix Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most accounts from Telix Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Telix Pharmaceuticals income statement Correlations

	Other Operating Expenses	Operating Income	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Depreciation And Amortization	Selling General Administrative	Net Income From Continuing Ops	Ebit	Research Development	Net Interest Income	Interest Income	Selling And Marketing Expenses	Reconciled Depreciation
Other Operating Expenses		0.4	0.14	0.99	-0.06	-0.95	-0.08	0.04	0.83	0.95	-0.08	0.06	0.99	-0.98	0.2	0.98	0.73
Operating Income	0.4		0.95	0.49	0.89	-0.33	0.87	0.47	-0.08	0.15	0.87	0.93	0.38	-0.29	0.04	0.55	-0.23
Ebitda	0.14	0.95		0.24	0.96	-0.1	0.97	0.37	-0.29	-0.14	0.97	1.0	0.13	-0.04	-0.03	0.31	-0.42
Total Operating Expenses	0.99	0.49	0.24		0.04	-0.93	0.03	0.02	0.79	0.9	0.03	0.17	0.99	-0.96	0.24	0.99	0.68
Income Before Tax	-0.06	0.89	0.96	0.04		0.14	0.98	0.51	-0.51	-0.31	0.98	0.98	-0.08	0.18	-0.03	0.1	-0.62
Total Other Income Expense Net	-0.95	-0.33	-0.1	-0.93	0.14		0.15	-0.01	-0.82	-0.92	0.15	-0.02	-0.93	0.95	0.08	-0.93	-0.74
Net Income	-0.08	0.87	0.97	0.03	0.98	0.15		0.35	-0.47	-0.35	1.0	0.98	-0.08	0.18	0.04	0.09	-0.57
Income Tax Expense	0.04	0.47	0.37	0.02	0.51	-0.01	0.35		-0.43	0.06	0.35	0.4	-0.04	0.08	-0.35	0.09	-0.49
Depreciation And Amortization	0.83	-0.08	-0.29	0.79	-0.51	-0.82	-0.47	-0.43		0.85	-0.47	-0.37	0.85	-0.88	0.27	0.75	0.97
Selling General Administrative	0.95	0.15	-0.14	0.9	-0.31	-0.92	-0.35	0.06	0.85		-0.35	-0.21	0.93	-0.96	0.13	0.89	0.78
Net Income From Continuing Ops	-0.08	0.87	0.97	0.03	0.98	0.15	1.0	0.35	-0.47	-0.35		0.98	-0.08	0.18	0.04	0.09	-0.57
Ebit	0.06	0.93	1.0	0.17	0.98	-0.02	0.98	0.4	-0.37	-0.21	0.98		0.05	0.04	-0.06	0.24	-0.49
Research Development	0.99	0.38	0.13	0.99	-0.08	-0.93	-0.08	-0.04	0.85	0.93	-0.08	0.05		-0.98	0.27	0.98	0.75
Net Interest Income	-0.98	-0.29	-0.04	-0.96	0.18	0.95	0.18	0.08	-0.88	-0.96	0.18	0.04	-0.98		-0.21	-0.95	-0.8
Interest Income	0.2	0.04	-0.03	0.24	-0.03	0.08	0.04	-0.35	0.27	0.13	0.04	-0.06	0.27	-0.21		0.18	0.28
Selling And Marketing Expenses	0.98	0.55	0.31	0.99	0.1	-0.93	0.09	0.09	0.75	0.89	0.09	0.24	0.98	-0.95	0.18		0.62
Reconciled Depreciation	0.73	-0.23	-0.42	0.68	-0.62	-0.74	-0.57	-0.49	0.97	0.78	-0.57	-0.49	0.75	-0.8	0.28	0.62

Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Telix Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	2.4M	1.2M	189K	406K	13.1M	13.8M
Other Operating Expenses	43.7M	54.5M	88.8M	233.3M	451.0M	473.6M
Operating Income	(40.3M)	(49.3M)	(81.2M)	(73.2M)	51.9M	54.5M
Ebitda	(36.2M)	(44.9M)	(70.1M)	(92.8M)	23.0M	24.1M
Total Operating Expenses	28.4M	32.4M	51.5M	102.5M	311.5M	327.1M
Income Before Tax	(42.8M)	(60.3M)	(99.0M)	(98.6M)	3.1M	3.2M
Total Other Income Expense Net	9.1M	(11M)	(17.8M)	(24.5M)	(48.8M)	(46.4M)
Net Income	(27.9M)	(44.9M)	(80.5M)	(104.1M)	5.2M	5.5M
Income Tax Expense	(14.9M)	(15.4M)	(18.5M)	5.5M	(2.1M)	(2.2M)
Depreciation And Amortization	4.2M	4.9M	5.2M	5.4M	6.7M	7.1M
Selling General Administrative	6.5M	7.7M	34.9M	77.3M	79.0M	82.9M
Total Revenue	3.5M	5.2M	7.6M	160.1M	496.7M	521.5M
Gross Profit	(11.9M)	(16.9M)	(29.8M)	29.3M	308.5M	323.9M
Net Income From Continuing Ops	(27.9M)	(44.9M)	(80.5M)	(104.1M)	5.2M	5.5M
Ebit	(40.4M)	(49.8M)	(75.2M)	(98.2M)	16.2M	17.0M
Research Development	21.2M	23.1M	34.1M	57.9M	128.8M	135.3M
Cost Of Revenue	15.4M	22.1M	37.4M	130.8M	188.2M	197.6M
Net Income Applicable To Common Shares	(27.9M)	(44.9M)	(80.5M)	(104.1M)	(93.7M)	(89.0M)
Tax Provision	(3.3M)	(3.0M)	45K	5.5M	(2.1M)	(2.0M)
Net Interest Income	(2.3M)	(1.1M)	(5.2M)	(6.7M)	(12.8M)	(12.1M)
Interest Income	2.4M	67K	163K	1K	1.0M	626.2K
Selling And Marketing Expenses	312K	1.2M	5.9M	16.2M	54.9M	57.6M
Reconciled Depreciation	4.2M	4.9M	5.2M	5.4M	6.7M	4.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC